Journals / Kocaeli Tıp Dergisi / 2020 / Cilt: 9 - Sayı: 3

The Effect of Extended Hydroxychloroquine in Intensive Care Management of Covid 19 on Survival and Costs

Covid 19'un Yoğun Bakım Yönetiminde Uzatılmış Hidroksiklorokinin Sağkalım ve Maliyetler Üzerindeki Etkisi

Pages
128–135
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients' age, gender, additional diseases, COVID-19 testings, hydroxychloroquine treatment days, invasive mechanical ventilator requirement and duration, intensive care hospitalization day, mortality and costs were recorded.RESULTS: The duration of hospitalization in patients in group 2 was longer than group 1 (9,4 days vs 13,8 days, p=0

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: There is a broad spectrum of action against most coronaviruses and especially viruses, including SARS-CoV-2.
📊
Key Findings & Data:While the hydroxychloroquine treatment recommendation in the national treatment guidelines was 5 days at the beginning of the pandemic, it was recommended as 10 days in cases where the clinic deteriorated under hydroxychloroquine treatment since 14 April.
💡
Conclusion & Impact:Patients' age, gender, additional diseases, COVID-19 testings, hydroxychloroquine treatment days, invasive mechanical ventilator requirement and duration, intensive care hospitalization day, mortality and costs were recorded.RESULTS: The duration of hospitalization in patients in group 2 was longer than group 1 (9,4 days vs 13,8 days, p=0
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: There is a broad spectrum of action against most coronaviruses and especially viruses, including SARS-CoV-2. While the hydroxychloroquine treatment recommendation in the national treatment guidelines was 5 days at the beginning of the pandemic, it was recommended as 10 days in cases where the clinic deteriorated under hydroxychloroquine treatment since 14 April. In this retrospective, observational, single-center study, it was aimed to reveal the effect of hydroxychloroquine treatment duration on the day of hospitalization, mechanical ventilation requirement, duration, survival and cost in patients with COVID-19 in intensive care unit.METHODS: Following the approval of the Ethics Committee, the data of the first 50 patients (Group 1) who received hydroxychloroquine for 5 days and the first 50 patients (Group 2) who received 10 days were included in the study. Patients' age, gender, additional diseases, COVID-19 testings, hydroxychloroquine treatment days, invasive mechanical ventilator requirement and duration, intensive care hospitalization day, mortality and costs were recorded.RESULTS: The duration of hospitalization in patients in group 2 was longer than group 1 (9,4 days vs 13,8 days, p=0

Özet

GİRİŞ ve AMAÇ: Hidroksiklorokin, çoğu koronavirüse ve özellikle SARS-CoV-2 dahil olmak üzere virüslere karşı geniş bir etki yelpazesi vardır. Ulusal tedavi kılavuzlarındaki hidroksiklorokin tedavi önerisi pandeminin başlangıcında 5 gün iken, 14 Nisan'dan itibaren hidroksiklorokin tedavisi altında kliniğin kötüleştiği durumlarda 10 gün olarak önerilmiştir. Bu retrospektif, gözlemsel, tek merkezli çalışmada, yoğun bakımda COVID-19 ile izlenen hastalarda hidroksiklorokin tedavi süresinin hastanede kalış günü, mekanik ventilasyon gereksinimi, süresi, sağkalıma ve maliyet üzerine etkisinin ortaya çıkarılması amaçlanmıştır.YÖNTEM ve GEREÇLER: Etik Kurul onayının ardından 5 gün süreyle hidroksiklorokin alan ilk 50 hastanın (Grup 1) ve 10 gün alan ilk 50 hastanın (Grup 2) verileri çalışmaya dahil edildi. Hastaların yaşı, cinsiyeti, ek hastalıkları, COVID-19 testleri, hidroksiklorokin tedavi günleri, invazif mekanik ventilatör ihtiyacı ve süresi, yoğun bakımda yatış günü, mortalite varlığı ve maliyetleri kaydedildi.BULGULAR: Grup 2'deki hastaların hastanede kalış süresi grup 1'den daha uzundu (9,4 güne karşı 13,8 gün, p = 0

🔖

Cite This Article

ÇİYİLTEPE, F., SARAÇOĞLU, K. T., BOMBACI, E., KAHRAMAN, E., SARAÇOĞLU, A., BİLİR, Y. (2022). The Effect of Extended Hydroxychloroquine in Intensive Care Management of Covid 19 on Survival and Costs. Kocaeli Tıp Dergisi, Cilt: 9 - Sayı: 3, 128–135. https://ajindex.com/articles/574759

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Zhou P., Yang XL., Wang XG., Hu B., Zhang L., Zhang W., et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020;579; 270–273. DOI: 10.1038/s41586-020-2012-7 2. Chen N., Zhou M., Dong X, Qu J., Gong F., Han Y., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel Coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395;507–513 DOI: 10.1016/S0140-6736(20)30211-7 3. Burkard C., Verheije M.H., Wicht O., vanKasteren S.I., vanKuppeveld F.J., Haagmans B.L., et. al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoSPathog 2014;10 DOI: 10.1371/journal.ppat.1004502 4. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., et. al.: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30;269-271. DOI:10.1038/s41422-020-0282-0 5. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral efects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents. 2020; 55(5):105938. DOI:10.1016/j.ijantimicag.2020.105938 Schönthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12. DOI: 10.3171/2014.12.focus14748 7. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Efects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–7. DOI: 10.1016/s1473-3099(03)00806-5 8. Gautret P., Lagier JC., Parola P., Hoang VT., Meddeb L., Mailhe M., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. J Antimicrob Agents 2020;20;105949. DOI: 10.1016/j.ijantimicag.2020.105949 9. J M Molina 1, C Delaugerre 2, J Le Goff 2, B Mela-Lima 3, D Ponscarme 3, L Goldwirt, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med et Mal Infect 2020; 50(4):384. DOI: 10.1016/j.medmal.2020.03.006 10. Chen J, Ping L, Liu, L, et al. A pilot study of hydroxychloroquine sulfate in patients with common 2019 coronavirus disease-19 (COVID-19). J ZheJiang University (Medical Sciences) 2020; 49(1):0-0. 11. Chen Z., Hu J., Zhang Z., Jiang S., Han S., Ya D., et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical tr